Biogen (BIIB) Could Be Worth $375-475/Share in a Takeover - RBC Capital's Yee
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Biogen (BIIB) Sale Dependent on Value of Aducanumab - BMO Capital
August 3, 2016 7:52 AM EDTBMO Capital analyst M. Ian Somaiya weighed in on Biogen (NASDAQ: BIIB) amid reports Tuesday that the company is in talks with Merck and Allergan on a potential takeout.
Somaiya said a potential sale, in their opinion, is likely dependent on Biogen's... More
Biogen (BIIB) Takeover 'Makes Sense' - Leerink Partners
August 3, 2016 7:38 AM EDTLeerink Partners analyst Geoffrey Porges weighed in on Biogen (NASDAQ: BIIB) amid reports Tuesday that the company is in talks with Merck and Allergan on a potential takeout.
Porges said while they have no information to confirm the suggestions that Merck (MP) and Allergan (OP) are among the potential suitors, it certainly makes sense to us.
"In our recent notes we have suggested... More
Tecfidera IP the Major Risk of Biogen (BIIB) Takeout - Baird
August 3, 2016 7:17 AM EDTBaird analyst Brian Skorney weighed in on Biogen (NASDAQ: BIIB) amid reports Tuesday that the company is in talks with Merck and Allergan on a potential takeout.
Skorney commented, "Though we are not surprised that takeout discussions are taking place, we question the... More
Standpoint Research Downgrades Biogen (BIIB) to Hold
August 2, 2016 3:31 PM EDTStandpoint Research downgraded Biogen (NASDAQ: BIIB) from Buy to Hold.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $301.83 yesterday.
... MoreiShares Nasdaq Biotechnology (IBB) Spikes on Biogen Headlines
August 2, 2016 2:52 PM EDTiShares Nasdaq Biotechnology (NASDAQ: IBB) spikes higher on reports Merck (NYSE: MRK) and Allergan (NYSE: AGN) were looking at Biogen (NASDAQ: BIIB)
... MoreBiogen (BIIB) Peers on Watch Amid M&A Chatter (AMGN) (GILD)
August 2, 2016 2:52 PM EDTBiogen (NASDAQ: BIIB) peers are on watch amid today's M&A chatter. Names include: Celgene (NASDAQ: CELG), Gilead Sciences (NASDAQ: GILD), and Amgen (NASDAQ: AMGN), among others.
... MoreBiogen (BIIB) Shares Active on M&A Chatter
August 2, 2016 2:43 PM EDT(Updated - August 2, 2016 2:46 PM EDT)
Biogen (NASDAQ: BIIB) shares volatile over Merck (NYSE: MRK), Allergan (NYSE: AGN)-related chatter.
UPDATE - Talks were said... More
Biogen (BIIB) Draws Takeover Interest from Allergan (AGN), Merck (MRK) - DJ
August 2, 2016 2:43 PM EDT(Updated - August 2, 2016 2:49 PM EDT)
Biogen (Nasdaq: BIIB) attracted takeover interest from Allergan (NYSE: AGN) and Merck (NYSE: MRK), according to Dow Jones, citing sources. The two companies reportedly... More
Biogen (BIIB) triggers LUDP trading pause
August 2, 2016 2:43 PM EDTBiogen (NASDAQ: BIIB) triggers LUDP trading pause.
... More